Ball S et al. Prognostic scoring systems and risk stratification in myelodysplastic syndrome: Focus on integration of molecular profile. Leuk Lymphoma 2021;[Online ahead of print]. Abstract
Brunner AM et al. Efficacy and safety of sabatolimab (MBG453) in combination with hypomethylating agents (HMAs) in patients (pts) with very high/high-risk myelodysplastic syndrome (vHR/HR-MDS) and acute myeloid leukemia (AML): Final analysis from a phase Ib study. ASH 2021;Abstract 244.
Chan O et al. Therapeutic outcomes and prognostic impact of gene mutations including TP53 and SF3B1 in patients with Del(5q) myelodysplastic syndromes (MDS). Clin Lymphoma Myeloma Leuk 2022;[Online ahead of print]. Abstract
Cluzeau T et al. Personalized medicine for TP53 mutated myelodysplastic syndromes and acute myeloid leukemia. Int J Mol Sci 2021;22(18):10105. Abstract
Fenaux P et al. Luspatercept in patients with lower-risk myelodysplastic syndromes. N Engl J Med 2020;382(2):140-51. Abstract
Garcia JS et al. Molecular responses are observed across mutational spectrum in treatment-naïve higher-risk myelodysplastic syndrome patients treated with venetoclax plus azacitidine. ASH 2021;Abstract 241.
Garcia-Manero G et al. Magrolimab + azacitidine versus azacitidine + placebo in untreated higher risk (HR) myelodysplastic syndrome (MDS): The phase 3, randomized, ENHANCE study. ASCO 2021;Abstract TPS7055.
Garcia-Manero G et al. Oral decitabine/cedazuridine in patients with lower risk myelodysplastic syndrome: A longer-term follow-up from the ASCERTAIN study. ASH 2021;Abstract 66.
Garcia-Manero G et al. Phase III, randomized, placebo-controlled trial of CC-486 (oral azacitidine) in patients with lower-risk myelodysplastic syndromes. J Clin Oncol 2021;39(13):1426-36. Abstract
Jain AG et al. Responses to Sars-Cov-2 vaccines in patients with myelodysplastic syndrome and acute myeloid leukemia. ASH 2021;Abstract 217.
Jain AG et al. The natural history of lower risk MDS: Factors predicting progression to high-risk myelodysplastic syndrome and acute myeloid leukemia in patients with very low and low risk MDS according to the R-IPSS criteria. ASH 2021;Abstract 2600.
Komrokji RS et al. Assessing the role of venetoclax in combination with hypomethylating agents in higher risk myelodysplastic syndromes. ASH 2021;Abstract 536.
Komrokji RS et al. IDH mutations are enriched in myelodysplastic syndromes patients with severe neutropenia: A potential targeted therapy. ASH 2021;Abstract 1526.
Komrokji RS et al. Luspatercept for myelodysplastic syndromes/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis. Leukemia 2022;[Online ahead of print]. Abstract
Mangaonkar AA et al. SF3B1-mutant myelodysplastic syndrome/myeloproliferative neoplasms: A unique molecular and prognostic entity. Haematologica 2022;[Online ahead of print]. Abstract
Padron, E et al. COVID-19 outcomes among participants in the NHLBI myelodysplastic syndromes (MDS) natural history study. ASH 2021;Abstract 2611.
Sallman DA et al. Tolerability and efficacy of the first-in-class anti-CD47 antibody magrolimab combined with azacitidine in MDS and AML patients: Phase Ib results. ASCO 2020;Abstract 7507.
Sekeres MA et al. Pevonedistat (PEV) + azacitidine (AZA) versus AZA alone as first-line treatment for patients with higher-risk myelodysplastic syndromes (MDS)/chronic myelomonocytic leukemia (CMML) or acute myeloid leukemia (AML) with 20-30% marrow blasts: The randomized phase 3 PANTHER trial (NCT03268954). ASH 2021;Abstract 242.
Tinsley-Vance SM et al. A focus on phenotype and genotype: Racial/ethnic disparities in myelodysplastic syndromes. ASH 2021;Abstract 1985.
Venugopal S et al. A phase I/II study of venetoclax in combination with ASTX727 (cedazuridine/decitabine) in treatment‐naïve high‐risk myelodysplastic syndrome (MDS) or chronic myelomonocytic leukemia (CMML). ASH 2021;Abstract 245.
Volpe VO et al. Myelodysplastic syndromes: A new decade. Clin Lymphoma Myeloma Leuk 2022;22(1):1-16. Abstract
Volpe VO, Komrokji RS. Treatment options for lower-risk myelodysplastic syndromes. Where are we now? Ther Adv Hematol 2021;12:1-10. Abstract
Zeidan AM et al. Phase 3 VERONA study of venetoclax with azacitidine to assess change in complete remission and overall survival in treatment-naïve higher-risk myelodysplastic syndromes. ASCO 2021;Abstract TPS7054.
Zeidan AM et al. Venetoclax and azacitidine in the treatment of patients with relapsed/refractory myelodysplastic syndrome. ASH 2021;Abstract 537.